Table 1 Baseline characteristics of total study population.
Breast cancer patients with PEGylated filgrastim (n = 2068) | |
|---|---|
Age, years | 49.9 ± 11.1 |
Sex | |
Female | 2065 (99.9%) |
Male | 3 (0.1%) |
Chemotherapy indication | |
Neoadjuvant | 995 (48.1%) |
Adjuvant | 1073 (51.9%) |
Chemotherapy regimen | |
Doxorubicin + cyclophosphamide | 243 (11.8%) |
Docetaxel + cyclophosphamide | 383 (18.5%) |
Docetaxel + doxorubicin + cyclophosphamide | 724 (35.0%) |
Docetaxel + carboplatin | 369 (17.8%) |
Others | 349 (16.9%) |
G-CSF with chemotherapy | |
PEGylated filgrastim | 2068 (100%) |
Pegfilgrastim | 1438 (69.5%) |
Tripegfilgrastim | 567 (27.4%) |
Pegfilgrastim and tripegfilgrastim | 63 (3.0%) |
G-CSF for febrile neuropenia | |
Filgrastim | 470 (22.7%) |
Lenograstim | 0 (0%) |
